Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

By sjmartinez • November 9, 2023

Karpouzas GA, Szekanecz Z, Baecklund E, Mikuls TR, Bhatt DL, Wang C, Sawyerr GA, Chen Y, Menon S, Connell CA, Ytterberg SR, Mortezavi M. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance. Ther Adv Musculoskelet Dis. 2023 Nov 6;15:1759720X231201047. doi: 10.1177/1759720X231201047. PMID: 37942277; PMCID: PMC10629315.

Tags: autoinflammatory conditions, DMARDs, Inflammation, outcome measures, Publications, Rheumatoid arthritis, Rheumatology

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis

Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark[...]

Hyperferritinemia as a Clue to Neuroendocrine Carcinoma

Chao ES, Yoshikawa G, Qing X, Huang C. Hyperferritinemia as a Clue to Neuroendocrine Carcinoma. Cureus. 2025 Aug 13;17(8):e90020. doi: 10.7759/cureus.90020. PMID: 40951183; PMCID: PMC12431798.

Identifying Core Clinical Topics and Recommending Core Performance Measures for Internal Medicine Physicians: A Position Paper From the American College of Physicians

Qaseem A, Fitterman N, Tierney S, Powell RE, Campos K, Choi EI, Crandall CJ, Cross JT Jr, Humphrey LL, Obley AJ, Wilt TJ, Andrews RA;[...]